Trial Profile
Efficacy and Safety of Immunomodulator (Mycobacterium w.) as an Adjunct Therapy in Category I Pulmonary Tuberculosis and Along With Assessment of Immunological Parameters
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Cadi 05 (Primary)
- Indications Pulmonary tuberculosis
- Focus Adverse reactions; Therapeutic Use
- 01 Oct 2014 New trial record